{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:37:36Z","timestamp":1792517856691,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01410-w","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:13:49Z","timestamp":1764155629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5252-4365","authenticated-orcid":false,"given":"Mathilde","family":"Kouwenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoletta","family":"Lendvai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-1244","authenticated-orcid":false,"given":"Kevin C.","family":"De Braganca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slaughter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Vlummens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Varsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Corsale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-7627","authenticated-orcid":false,"given":"Erin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreta","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-min","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicki","family":"Plaks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-7240","authenticated-orcid":false,"given":"Rocio","family":"Montes de Oca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Florendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mythili","family":"Koneru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9423-4059","authenticated-orcid":false,"given":"Bianca D.","family":"Santomasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2969-0116","authenticated-orcid":false,"given":"Jaime","family":"G\u00e1llego Perez-Larraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels WCJ","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"1410_CR2","unstructured":"Janssen Biotech, Inc., Legend Biotech: CARVYKTI\u00ae (ciltacabtagene autoleucel) suspension for intravenous infusion [prescribing information]. 2024. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/CARVYKTI-pi.pdf."},{"key":"1410_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141:219\u201330.","journal-title":"Blood"},{"key":"1410_CR4","doi-asserted-by":"publisher","first-page":"8020","DOI":"10.1200\/JCO.2022.40.16_suppl.8020","volume":"40","author":"H Einsele","year":"2022","unstructured":"Einsele H, Cohen AD, Delforge M, Hillengass J, Goldschmidt H, Weisel K, et al. Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1\u20133 prior lines of therapy (LOT): CARTITUDE-2, cohort A. J Clin Oncol. 2022;40:8020.","journal-title":"J Clin Oncol"},{"key":"1410_CR5","doi-asserted-by":"crossref","unstructured":"Van de Donk NWCJ, Agha M, Cohen AD, Cohen YC, Anguille S, Kerre T, et al. Ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2 cohort B 18-month follow-up. Blood. 2022;140:7536\u20137.","DOI":"10.1182\/blood-2022-159169"},{"key":"1410_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1410_CR7","first-page":"259","volume":"8","author":"LN Gonzalez Castro","year":"2021","unstructured":"Gonzalez Castro LN, Dietrich J. Evaluation and management of chimeric antigen receptor (CAR) T-cell-associated neurotoxicity. Neurooncol Pract. 2021;8:259\u201365.","journal-title":"Neurooncol Pract"},{"key":"1410_CR8","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol"},{"key":"1410_CR9","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","volume":"8","author":"AB Leahy","year":"2021","unstructured":"Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematol. 2021;8:e711\u201322.","journal-title":"Lancet Haematol"},{"key":"1410_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1200\/JCO.20.03585","volume":"40","author":"LM Schultz","year":"2022","unstructured":"Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022;40:945\u201355.","journal-title":"J Clin Oncol"},{"key":"1410_CR11","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/S2152-2650(24)01905-0","volume":"24","author":"R Abonour","year":"2024","unstructured":"Abonour R, Kitali A, Gipson A, Trovato A, Shanker M, Chiang M, et al. P-002 Ide-cel real-world (RW) and clinical trial long-term safety experience: a special focus on movement and neurocognitive treatment adverse events (MNT AEs) and second primary malignancies (SPMs). Clin Lymphoma Myeloma Leuk. 2024;24:S40\u20131.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1410_CR12","doi-asserted-by":"crossref","unstructured":"Spencer A, Raab M-S, Iida S, Mateos M-V, Cavo M, Rodriguez-Otero P, et al. Interim phase 2 study results of durcabtagene autoleucel (PHE885), a T-charge\u2122 manufactured BCMA-directed CAR-T cell therapy in patients (pts) with r\/r multiple myeloma (RRMM). [Oral Presentation]. Presented at: 21st International Myeloma Society Annual Meeting; Sept 25\u201328 2024; Rio de Janeiro, Brazil.","DOI":"10.1016\/S2152-2650(24)01853-6"},{"key":"1410_CR13","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1007\/s00415-019-09282-4","volume":"267","author":"W Zhang","year":"2020","unstructured":"Zhang W, Xu L, Luo T, Wu F, Zhao B, Li X. The etiology of Bell\u2019s palsy: a review. J Neurol. 2020;267:1896\u2013905.","journal-title":"J Neurol"},{"key":"1410_CR14","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","volume":"24","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2024;24:e217\u201325.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1410_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2024","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2024;145:85\u201397.","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01410-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01410-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01410-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:13:51Z","timestamp":1764155631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01410-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01410-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Paula Rodr\u00edguez-Otero Consulting or advisory role: AbbVie, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Oncopeptides, Pfizer, Roche, Sanofi. Travel, accommodations, and expenses: Pfizer. Honoraria: Amgen, Bristol Myers Squibb, GlaxoSmithKline, H3 Biomedicine, Johnson & Johnson, Regeneron, Sanofi. Surbhi Sidana Consulting or advisory role: AbbVie, Bristol Myers Squibb, Johnson & Johnson, Kite, Legend Biotech USA Inc., Magenta Therapeutics, Oncopeptides, Pfizer, Regeneron, Sanofi, Takeda.\n                      Research funding:\n                      Allogene, Bristol Myers Squibb, Johnson & Johnson, Magenta Therapeutics, Novartis.\n                      Mathilde Kouwenhoven\n                      No conflicts of interest.\n                      Jordan M. Schecter Employment and patent and royalty interests:\n                      Johnson & Johnson\n                      Equity:\n                      Johnson & Johnson.\n                      Nikoletta Lendvai Employment:\n                      Johnson & Johnson\n                      Stock options:\n                      Johnson & Johnson.\n                      Kevin C. De Braganca Employment:\n                      Johnson & Johnson.\n                      Ana Slaughter Employment:\n                      Johnson & Johnson\n                      Equity:\n                      a privately held company\n                      Stock options:\n                      a privately held company.\n                      Carolina Lonardi Employment:\n                      Johnson & Johnson.\n                      Philip Vlummens Employment:\n                      Johnson & Johnson (at the time the work was performed).\n                      Stock options:\n                      Johnson & Johnson.\n                      Helen Varsos Employment:\n                      Johnson & Johnson.\n                      Equity:\n                      Johnson & Johnson.\n                      Christina Corsale Employment:\n                      Johnson & Johnson\n                      Equity:\n                      a publicly traded company.\n                      Deepu Madduri Employment:\n                      Johnson & Johnson.\n                      Hao Zhao Employment:\n                      Johnson & Johnson.\n                      Katherine Li Employment:\n                      Johnson & Johnson\n                      Equity:\n                      Johnson & Johnson.\n                      Erin Lee Employment:\n                      Johnson & Johnson\n                      Equity:\n                      Johnson & Johnson.\n                      Loreta Marquez Employment:\n                      Johnson & Johnson\n                      Equity:\n                      Johnson & Johnson\n                      Divested equity in the past 24 months:\n                      Johnson & Johnson.\n                      Man Zhao Employment:\n                      IQVIA.\n                      Tzu-min Yeh Employment:\n                      Johnson & Johnson\n                      Equity:\n                      Johnson & Johnson\n                      Stock options:\n                      Johnson & Johnson.\n                      Diana Chen Employment:\n                      Johnson & Johnson\n                      Stock options and other ownership interests:\n                      Johnson & Johnson.\n                      Vicki Plaks\n                      Employment:\n                      Johnson & Johnson\n                      Equity:\n                      Johnson & Johnson.\n                      Rocio Montes de Oca\n                      Employment:\n                      Johnson & Johnson.\n                      Stock options and other ownership interests:\n                      Johnson & Johnson.\n                      Erika Florendo Employment:\n                      Legend Biotech USA Inc.\n                      Equity:\n                      a publicly traded company.\n                      Nitin Patel Employment:\n                      Legend Biotech USA Inc.\n                      Equity:\n                      Legend Biotech USA Inc.\n                      Muhammad Akram Employment:\n                      Legend Biotech USA Inc.\n                      Equity:\n                      a publicly traded company.\n                      Mythili Koneru\n                      Employment:\n                      Legend Biotech USA Inc.\n                      Stock options and other ownership interests:\n                      Legend Biotech USA Inc.\n                      Bianca D. Santomasso Consulting or advisory role:\n                      Bristol Myers Squibb\/Celgene, Gilead Sciences, IN8Bio, Johnson & Johnson.\n                      Jaime G\u00e1llego Perez-Larraya Consulting or advisory role and honoraria:\n                      GlaxoSmithKline, Johnson & Johnson.\n                      Travel, accommodations, and expenses:\n                      Janssen.\n                      Niels WCJ van de Donk Consulting or advisory role:\n                      AbbVie, Adaptive Biotechnologies, Amgen, Bayer, Bristol Myers Squibb\/Celgene, Galapagos, Johnson & Johnson, Kite, Merck, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Servier, Takeda\n                      Research funding:\n                      Amgen, Bristol Myers Squibb\/Celgene, Cellectis, Johnson & Johnson, Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The CARTITUDE-1, CARTITUDE-2, and CARTITUDE-4 trials were conducted in accordance with the Declaration of Helsinki and International Council for Harmonisation Guidelines for Good Clinical Practice. All patients provided written informed consent. For each trial, the independent ethics committee or institutional review board at each site approved the trial protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and patient consent"}}],"article-number":"209"}}